Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04209621
Title Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Heart, Lung, and Blood Institute (NHLBI)
Indications

chronic lymphocytic leukemia

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Duvelisib + Ibrutinib

Age Groups:
Covered Countries USA


No variant requirements are available.